Drugs / LB80380
LB80380
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00895596 | Mar 2004 → Aug 2006 | chronic hepatitis B virus infection | LG Life Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01242787 | Aug 2010 → Sep 2012 | chronic hepatitis B virus infection | LG Life Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01026610 | Aug 2009 → Nov 2010 | chronic hepatitis B virus infection | LG Life Sciences | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03885778 | Jan 2019 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 4 | NCT03604016 | Sep 2018 → Jul 2020 | hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB80380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01242787 ↗ |
| Known as | An-380 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1652128 ↗ |
| Known as | Besifovir dipivoxil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03604016 ↗ |
| Known as | Pmcdg dipivoxil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1652128 ↗ |
| Modality | Small molecule | “a new nucleotide analogue, LB80380” PMID 20091678 ↗ Mar 2010 |
| Route | Oral | “ascending multiple oral doses of LB80380” NCT00895596 ↗ |